Kornimate/medical-research-clean huggingface dataset:
nurse-led heart math training program with substance use disorder

Conditions: Substance Abuse

Summary: substance use disorders (suds) pose significant challenges to individuals' psychological well-being, resilience, and emotional adjustment. these disorders often lead to detrimental effects on physical health, mental health, and overall quality of life, creating a critical need for effective interventions that can support recovery and enhance emotional resilience. one promising approach is the implementation of nurse-led heartmath training programs. these programs utilize evidence-based techniques to improve emotional regulation, increase resilience, and foster a sense of coherence, which is the ability to perceive life as comprehensible, manageable, and meaningful.

the heartmath training program, developed by the heartmath institute, focuses on teaching individuals self-regulation skills that promote heart-brain coherence. this state of coherence has been associated with improved cognitive function, emotional stability, and physical health. by integrating this training into the care of patients with suds, nurses can play a pivotal role in addressing the complex emotional and psychological needs of this population. brief about the training program the nurse-led heartmath training program consists of several key components designed to enhance resilience, sense of coherence, and emotional adjustment: heart-focused breathing techniques: patients are taught specific breathing techniques that help synchronize heart and brain activity, leading to a state of physiological coherence. emotional regulation skills: the training includes exercises that help individuals recognize and shift from negative to positive emotional states, thereby improving emotional stability and reducing stress. biofeedback technology: participants use heartmath biofeedback devices that provide real-time feedback on their heart rhythm patterns, enabling them to monitor and improve their coherence levels. resilience-building exercises: the program incorporates activities and practices aimed at enhancing personal resilience, such as positive visualization and the cultivation of gratitude and appreciation. individual and group sessions: the training is delivered through a combination of individual coaching and group workshops, providing both personalized support and a sense of community.

Eligibility criteria:
inclusion criteria: * substance abuse for at least one month exclusion criteria: * out side hospital
comparison between epinephrine and exercise test in qt long syndrome patients

Conditions: Long QT Syndrome Type 1 or 2

Summary: the aim of the study is to evaluate the best stress exam to unmask long qt in patient with kcnq1 or kcnh2 mutation without long qt interval in rest electrocardiogram.

65 patients with kcnq1 or kcnh2 mutation presenting qtc interval \<470msec and 65 patients without kcnq1 or kcnh2 mutation presenting qtc interval \<470msec will be included. all patients will have the 2 tests: exercise test and epinephrine test, in one half day. at the end of the inclusions, two experts will examine examens results without knowing in which arm (mutated or not) the patient belongs.

Eligibility criteria:
inclusion criteria: patients with qtc\<470 msec, and with molecular analysis (kcnq1 or kcnh2 genes) performed in order to include 65 patients with kcnq1 or kcnh2 mutation and 65 patients without kcnq1 or kcnh2 mutation (controls). exclusion criteria: * qtc interval \>470msec * treatment interfering with cardiac repolarisation * under 15 years old * pregnant women * contraindication to exercise or epinephrine tests * patients without social coverage

Keywords: long qt syndrome, stress tests
teaching inhaler use with the inca device in a community pharmacy setting

Conditions: Asthma; Pulmonary Disease, Chronic Obstructive

Summary: the purpose of this trial is to discover whether providing feedback to patients from a device that records when and how well a patient uses a seretide diskus inhaler will lead to: * improved compliance with prescribed inhaler use * improved technique of inhaler use * a reduction in respiratory health related outcomes caused by poor inhaler compliance and usage. * an improvement in patient quality of life scores


Eligibility criteria:
inclusion criteria: * must be 18 years old or above * capable of understanding and willing to provide voluntary informed consent before any protocol specific procedures are performed * capable of understanding and complying with the requirements of the protocol, and demonstrating a willingness to attend for all required visits. * able and willing to take inhaled medication. * have a valid prescription for use of a seretide diskus inhaler or already using a seretide diskus inhaler. * have a history of regular attendance in the pharmacy in which they are recruited which will be demonstrated by the subject having collected three prescriptions for any medication in that pharmacy in the six months preceeding their recruitment to the study. exclusion criteria: * patient expressly reports that their physician has indicated that they will not be continuing to receive seretide over the next 6 months

Keywords: medication adherence patient compliance
safety and dialysability of dotarem® in dialysed patients

Conditions: End-stage Renal Failure

Summary: to evaluate the dialysability of dotarem®, after an iv injection of 0.1 mmol/kg in patients with chronic renal failure who require hemodialysis treatment.

ten adult patients suffering from end stage renal failure and requiring hemodialysis treatment for 3 times were enrolled. patients received a single dose of dotarem® at 0.1 mmol/kg before being submitted to hemodialysis to assess the dialysability of dotarem® . after injection of dotarem®, 3 sessions of hemodialysis were performed as follows: the first hemodialysis session started between 1 to 2 h after the injection; the second hemodialysis session occurred 2 days (i.e., 48 ± 2 h) after the dotarem® injection; the third hemodialysis session occurred 4 days (i.e., 96 ± 4 h) after the dotarem® injection. the decrease in serum dotarem® concentration was assessed after each hemodialysis session. safety assessments included adverse events (aes), vital signs, injection-site tolerance, and laboratory assessments.two safety follow-up visits were performed: one 3 weeks (± 2 days) and one 3 months (± 4 days) after the dotarem® injection.

Eligibility criteria:
inclusion criteria: male or female, aged ≥18 years * subjects suffering from end-stage renal failure who require hemodialysis treatment for 3 times per week (or equivalent to allow overnight dialysis being rescheduled as appropriate per protocol) * female subjects with effective contraception (contraceptive pill or intra-uterine device), or surgically sterilized or post-menopausal (minimum 12 months amenorrhea) * subjects having provided their written informed consent to participate in the trial exclusion criteria: * known allergy to gadolinium chelates * pregnant, breast feeding, or planning to become pregnant during the trial * having received or scheduled to be injected with any contrast agent within 7 days before or after the dotarem® injection * schedule to receive erythropoietin (epo) or iron therapy during 1 week after the dotarem® injection * evidence of human immunodeficiency virus (hiv) infection and/or positive human hiv antibodies * evidence of hepatitis c and/or positive hepatitis c antibody and/or positive hepatitis b surface antigen * history of hypersensitivity to drugs with a similar chemical structure

Keywords: dotarem dialyses dialysed safety safety and dialysability of dotarem in dialysed patients
a postpartum adaptation study of the connecting and reflecting experience parenting program

Conditions: Postpartum Depression; Postpartum Anxiety; Parenting Stress; Parent Child Relationships

Summary: experiencing postpartum mood and/or anxiety disorders (like postpartum depression; pmads) can make parenting challenging, but group therapy may help both these parents and their babies. this study will test whether postpartum parents with pmads find a 12-session parenting group therapy to be likable, doable, and helpful for mental health, parenting stress, and relationship with their infant. the therapy that is being tested is called the connecting and reflecting experience (care) parenting program, which has not yet been used specifically with postpartum parents with pmads, but has been found to be appealing and helpful among parents/caregivers of older children with mental health conditions. care focuses on parents' ability to consider how their own and their children's thoughts, feelings, intentions, and other mental states shape behavior and parent-child relationships. participants in the study will be asked to fill out surveys before, during, and after participating in the group therapy. adults may be eligible to participate in the study if they gave birth to an infant who is now 3 to 12 months old, are receiving postpartum medical and/or mental health care at montefiore medical center, and have experienced postpartum depression and/or anxiety.


Eligibility criteria:
inclusion criteria: * birthing parent (of any gender) of an infant age 3-12 months old at baseline * receiving postpartum ob/gyn or mental health services at montefiore medical center * experienced or currently experiencing moderate to high levels of depression and/or anxiety symptoms in the postpartum period * english-speaking exclusion criteria: * prior participation in a connecting and reflecting experience (care) group at any time * participation in another parenting-focused group during the current postpartum period * current episode of psychosis or mania * psychiatric, neurocognitive, or substance use related difficulties necessitating a higher level of care than outpatient support (e.g., current inpatient treatment) or that would impede group participation (e.g., severe cognitive impairment)

Keywords: postpartum depression group therapy parenting stress short-term therapy parenting support postpartum anxiety perinatal mood and anxiety disorders mentalizing parental reflective functioning attachment
measurement of endothelial function with peripheral arterial tonometry in patients undergoing hyperbaric oxygen therapy

Conditions: Diabetic Peripheral Vascular Disease

Summary: the purpose of this clinical study is to test whether or not patients treated with hbot for diabetic foot ulcers will demonstrate measurable changes of the blood vessel function during the course of hbot treatments. , i.e. an expected increase in the reactive hyperemic index (rhi) measured by the peripheral arterial tonometry (pat).

measurement and monitoring of endothelial function can be used for prediction of outcome in acute, severe disease. diabetic patients have a poorer peripheral vascular function measured by peripheral arterial tonometry (pat) as compared to normals, but the effect of hyperbaric oxygen therapy (hbot) on endothelial function in these patients is unknown. measurement of pat in patients with diabetic foot ulcers undergoing hbot, may help to improve treatment and changes in the reactive hyperemic index (rhi) might correlate with wound healing in these patients. peripheral arterial tonometer (pat) has been shown to be an easy, fast and standardized method for measuring the peripheral arterial endothelial function. the method is also operator-independent and has a high reproducibility. the pat apparatus (endopat) measures the post-ischemic response to a five-minute blood flow occlusion of the upper arm, and the relationship between the pre-and post-ischemic pulse amplitude is expressed as a reactive hyperemic index (rhi). the normal rhi in young healthy persons is more than 2, while in critically ill patients and patients with diabetes, hypertension or heart disease it is significantly decreased. the study aims to test whether or not patients treated with hbot for diabetic foot ulcers will demonstrate an improvement of the endothelial function in the peripheral vessels, i.e. an increase in rhi measured by the pat. similarly, essential mediators of angiogenesis and nitric oxide bioavailability will be measured in peripheral blood taken during the pat measurements which will be performed at the time of inclusion, before hbot and subsequently for each 10th hbot session.

Eligibility criteria:
inclusion criteria: * diabetic patients with foot ulcer * none diabetic patients * age \> 18 years * patients referred to hyperbaric oxygen therapy. * patients who have given written informed consent to participate in the study exclusion criteria: * patients who cannot cooperate to participate in the study * patients who do not understand or speak danish or english * allergy to the materials used in the experiment. * patients \< 18 years

Keywords: diabetes foot wounds nitric oxide endothelium infection biological markers observational study hyperbaric oxygen ulcers cytokines inflammation
a study of retatrutide (ly3437943) in participants who have obesity or overweight

Conditions: Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea

Summary: the purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (j1i-mc-gzbj master protocol) including subsets of participants who have knee osteoarthritis (oa) (j1i-mc-goa1) or who have obstructive sleep apnea (osa) (j1i-mc-gsa1). this study will last about 89 weeks and will include up to 24 visits. addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.


Eligibility criteria:
inclusion criteria: * have body mass index (bmi) ≥30.0 kilograms per square meter (kg/m²), or ≥27.0 kg/m² with at least one of the following: * hypertension * dyslipidemia * obstructive sleep apnea, or * cardiovascular disease * history of of at least one unsuccessful dietary effort to reduce body weight goa1 inclusion criteria: * have index knee pain for \>12 weeks prior to screening, and presence of index knee pain for \>15 days over the previous month * have knee x-ray with moderate radiographic changes (kellgren-lawrence grade 2 or 3) per central reading at screening * currently meets american college of rheumatology (acr) criteria (clinical and radiological) for oa. gsa1 inclusion criteria: * previously diagnosed with osa * have ahi ≥15 on polysomnography at screening (definition of moderate-to-severe osa) * for participants not on positive airway pressure (pap) therapy: unable or unwilling to use pap therapy and have not used pap for at least 4 weeks prior to screening. * if on pap therapy, have been on pap therapy for at least 3 consecutive months prior to screening, and willing to temporarily stop using pap therapy for approximately 7 days prior to each of the sleep study (psg) visits. gzbj addenda (2) inclusion criteria: * have completed the final treatment visit of gzbj week 80. exclusion criteria: * have a self-reported or documented change in body weight \>5 kg (11 pounds) within 90 days. * have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening. * have a prior or planned surgical treatment for obesity. * have diabetes mellitus. * have family or personal history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men-2) * have had pancreatitis. goa1 exclusion criteria * have had steroid joint injections within 90 days of screening. * have had other joint injections and procedures within 6 months of screening. * have joint disease other than osteoarthritis. gsa1 exclusion criteria * use stimulants (for example, modafinil, armodafinil, solriamfetol, pitolisant, amphetamine) less than 3 months prior to screening. * use hypnotics, mirtazapine, opioids, trazodone, and zonisamide less than 3 months prior to screening. * use a dental appliance or other device to treat osa other than pap therapy. gzbj addenda (2) exclusion criteria * have had study intervention discontinuation. * have had permanent dose reduction.
comparison of acoustic attenuation parameter using fibrotouch with liver biopsy for diagnosis of hepatic steatosis

Conditions: Fatty Liver; Hepatic Steatosis; Liver Steatosis

Summary: this will be a multi-center, prospective, controlled study. it is expected that about 240 subjects from 10 study centers will be enrolled, and 224 effective subjects will be statistically analyzed in the end, in which 56 effective subjects with stage f0 (25%), 56 effective subjects with stage f1 (25%), 56 effective subjects with stage f2 (25%), 56 effective subjects with stage f3 (25%). by comparison of the result of fibrotouch examination with that of liver biopsy, their specificities, sensitivities and accuracies for diagnosis of liver steatosis will be identified. the patients with liver diseases who need to have a liver biopsy in hospital and meet all of the inclusion criteria and none of the exclusion criteria, may participate in this study. within two weeks of fibrotouch examination, subjects are required to have qualified histological specimens of liver biopsy for comparation.


Eligibility criteria:
inclusion criteria: * subject at the age of 18 to 65 years, non-limited gender. * within two weeks of fibrotouch examination, qualified histological specimens of liver biopsy are required. using the liver biopsy needle of 16g or 14ct, puncture and remove more than 2.0 centimeters long liver tissue (including at least 11 portal areas, no less than 6 complete portal areas and the minimum length of specimen should be more than 1.0 centimeter). * willing and able to abide by all principles and complete all study procedures. * willing and can provide written informed consent form by patient or patient's legal guardian. exclusion criteria: * subject with active or suspected cancer or history of malignant tumor by evidence within 5 years before enrolling. and the subject who has the liver malignant tumors injury cannot participate in this study. * there is evidence that the subject has a history of alcohol overdoses\* or drug abuse. definition of alcohol overdoses: 40 gram (g)/day for male and 40 g/day for female. alcohol intake (g) = the volume of drinking (ml) × alcohol percentage (%, v/v) × 0.8 (g/ml); 1g alcohol is the equal of 25-40 ml of beer, 8-10ml of chinese rice wine, 5-12ml of (grape) wine, 3-7ml of health care liquor or chinese spirits. * subject with alcoholic liver disease and hepatitis c. * pregnant or nursing woman, and subject with a pregnant plan and is unwilling to take contraceptive measures during this study. * subject with history of organ transplantation or has functional grafts (except for the cornea or hair graft). * subject with non-healing wound on the right upper abdomen at this moment. * in the investigator's opinion, the subject is unsuitable to participate in the study as he or she has a history of serious illness, or other evidence shown that the subject has any other serious illness. * subject who participates in other clinical trial at the same time.

Keywords: fibrotouch acoustic attenuation parameter liver biopsy hepatic steatosis
soft tissue and bone diameter in children and adults for intraosseus access

Conditions: Emergencies; Infusion Site Injury; Bone Infection

Summary: retrospective observational study: soft tissue and bone diameters are assessed in mri and ct scans of patients. data is compared with recommendations of intraosseus needle producers to assess whether the information provided by the producers can be optimised. study sites are head of humerus bone, distal femur, proximal and distal tibia in accordance with recommended intraosseus access sites. primary and secondary outcome parameters will be assessed at one time only, i.e. when the patient has received mri or ct scan for the diagnostic work up of their primary disease. data collection for a given patient in this study can be completed within one session, e.g. 5-10 minutes. no additional investigation is required for this retrospective study.

retrospective observational single centre study: soft tissue and bone diameters are assessed in mri and ct scans of patients. data is compared with recommendations of intraosseus needle producers to assess whether the information provided by the producers can be optimised. study sites are head of humerus bone, distal femur, proximal and distal tibia in accordance with recommended intraosseus access sites. data is gathered from patients who undergo either mri or ct scanning for any disease and where bone at the io puncture site is accessible for measurements required for this study. primary and secondary outcome parameters will be assessed at one time only, i.e. when the patient has received mri or ct scan for the diagnostic work up of their primary disease. data collection for a given patient in this study can be completed within one session, e.g. 5-10 minutes. no additional investigation is required for this

Eligibility criteria:
inclusion criteria: * patients 0-90 years of age with elective or emergency mri or ct scan within a 24 months period at the university hospital innsbruck, austria. patients in analgosedation, anaesthesia, and stand-by exclusion criteria: * pathologies at recommended intraosseus puncture - and investigation- site, i.e. proximal humerus, distal femur, proximal and distal tibia

Keywords: bone access intraosseus needle resuscitation infusion volume therapy emergency
mri biomarkers for radiation-induced neurocognitive decline following srs of newly diagnosed brain mets

Conditions: Brain Metastases; Neurocognitive Deficit; White Matter Alterations; Radiation Exposure

Summary: brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. with improvements in systemic therapy that prolong survival but have limited central nervous system penetration, patients with brain metastases are at increasing risk of developing and experiencing long-term side effects from treatment of brain metastases. the overarching goal of this study is to better understand the determinants of rt-associated changes in white and gray matter function and associated neurocognitive decline.

the proposed study aims to provide novel and useful information for clinicians, both to help predict potential neurocognitive changes following srs, and as a possible guide for srs treatment alteration, whether through adjustment of dose or beam arrangements in relation to white matter tracts. in this observational pilot study of 20 patients, the association between rt-associated brain injury and neurocognitive function will be quantitatively assessed longitudinally over one year following srs. the study team hypothesizes that, over this time, (1) there will be radiation dose-dependent reductions in regional white matter tract integrity and reduction in functional connectivity in the default mode network of gray matter, (2) there will be measurable decline in neurocognitive function, and (3) there will be an association between severity of radiation-induced brain injury on mri and magnitude of neurocognitive functional decline. this association will relate, in part, to the location(s) affected.

Eligibility criteria:
inclusion criteria: * histologic diagnosis of cancer * newly diagnosed brain metastasis being treated with srs. any extent of cranial disease permitted. subsequent courses of srs while on study permitted when clinically indicated. * patients are permitted to have undergone craniotomy and resection of metastasis/metastases if at least 1 other intact metastasis planned for definitive srs is present. receiving or previously received systemic therapy also permitted. * anticipated life expectancy at least 1 year * age ≥ 18 years * ability to read and comprehend written english and follow instructions in english * ability to provide informed consent exclusion criteria: * previous radiation to the brain or head * previous malignancy - other than non-melanomatous skin cancer or cervical carcinoma in situ - and not disease-free for at least 3 years * previous severe head or brain injury * history of a neurological disorder such as epilepsy, parkinson's, alzheimer's, or dementia * prisoners